Case Report
Treatment of Growth Hormone Deficiency via Daily Intravascular Injections in a Child with Bleeding Disorder
Table 1
Laboratory results of selected biomarkers of the patient before and after growth hormone treatment.
| Age (years, months) | 25/12 years (before rhGH) | 32/12 years (before rhGH) | 52/12 years (5 months after rhGH) | 61/12 years (16 months after rhGH) |
| IGF1 concentration (ng/mL) | <15 | <15 | 29 | 41 | IGF1 SDS score | | | −2.33 | −2.17 | IGFBP3 concentration (mg/L, RR: 0.8–3.9) | 0.65 | 0.8 | 1.6 | | TSH (mIU/L) | 2.1 | | 2.6 | 1.3 | Free T4 (ng/dL) | 1.1 | | 0.9 | 0.9 | Albumin (gr/dL) | | | 4.3 | | ALT (IU/L) | | | 27 | | AST (IU/L) | | | 20 | | HbA1c (%) | | | 4.7 | 4.5 | Protein C functional (%, RR: 40–92) | 14 | 14 | 11 | 12 |
|
|